Orion Biotechnology

Orion is a clinical stage company leveraging a proprietary technology platform to develop next generation therapeutics for effectively targeting G Protein-Coupled Receptors (GPCRs). Orion’s platform enables effectively targeting previously undruggable complex GPCRs. Our pipeline includes 3 next generation therapeutics for cancer including our lead candidate - OB-002 – which is a first-in-class cancer immunotherapy with best-in-class potency.